{"id":"https://openalex.org/W7223155019","doi":"https://doi.org/10.1016/j.htct.2026.107868","title":"EFFICACY AND SAFETY OF BISPECIFIC ANTIBODIES IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: A REAL-WORLD STUDY FROM BRAZIL","display_name":"EFFICACY AND SAFETY OF BISPECIFIC ANTIBODIES IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: A REAL-WORLD STUDY FROM BRAZIL","publication_year":2026,"publication_date":"2026-10-01","ids":{"openalex":"https://openalex.org/W7223155019","doi":"https://doi.org/10.1016/j.htct.2026.107868"},"language":"en","primary_location":{"id":"doi:10.1016/j.htct.2026.107868","doi":"https://doi.org/10.1016/j.htct.2026.107868","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.htct.2026.107868","pdf_url":"https://www.sciencedirect.com/science/article/pii/S2531137926016159/pdf","source":{"id":"https://openalex.org/S2898598332","display_name":"Hematology Transfusion and Cell Therapy","issn_l":"2531-1379","issn":["2531-1379","2531-1387"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","ki-jl-1","poland-20","russia-white-list-3","scielo"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Hematology, Transfusion and Cell Therapy","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"diamond","oa_url":"https://www.sciencedirect.com/science/article/pii/S2531137926016159/pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5159181633","display_name":"Humberto Humberto VILLEFORT","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I3019035496","display_name":"AC Camargo Hospital","ror":"https://ror.org/03025ga79","country_code":"BR","type":"healthcare","lineage":["https://openalex.org/I3019035496"]}],"countries":["BR"],"is_corresponding":false,"raw_author_name":"Humberto Humberto VILLEFORT","raw_affiliation_strings":["A. C. Camargo Cancer Center, S\u00e3o Paulo, SP, Brasil"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"A. C. Camargo Cancer Center, S\u00e3o Paulo, SP, Brasil","institution_ids":["https://openalex.org/I3019035496"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5159196624","display_name":"Giovanna Alves PERUZINI","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I3019035496","display_name":"AC Camargo Hospital","ror":"https://ror.org/03025ga79","country_code":"BR","type":"healthcare","lineage":["https://openalex.org/I3019035496"]}],"countries":["BR"],"is_corresponding":false,"raw_author_name":"Giovanna Alves PERUZINI","raw_affiliation_strings":["A. C. Camargo Cancer Center, S\u00e3o Paulo, SP, Brasil"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"A. C. Camargo Cancer Center, S\u00e3o Paulo, SP, Brasil","institution_ids":["https://openalex.org/I3019035496"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5107572082","display_name":"Julia Curi Amarante","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I3019035496","display_name":"AC Camargo Hospital","ror":"https://ror.org/03025ga79","country_code":"BR","type":"healthcare","lineage":["https://openalex.org/I3019035496"]}],"countries":["BR"],"is_corresponding":false,"raw_author_name":"Julia Curi AMARANTE","raw_affiliation_strings":["A. C. Camargo Cancer Center, S\u00e3o Paulo, SP, Brasil"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"A. C. Camargo Cancer Center, S\u00e3o Paulo, SP, Brasil","institution_ids":["https://openalex.org/I3019035496"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5107508881","display_name":"Vanessa A Bovolenta","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I3019035496","display_name":"AC Camargo Hospital","ror":"https://ror.org/03025ga79","country_code":"BR","type":"healthcare","lineage":["https://openalex.org/I3019035496"]}],"countries":["BR"],"is_corresponding":false,"raw_author_name":"Vanessa dos Anjos BOVOLENTA","raw_affiliation_strings":["A. C. Camargo Cancer Center, S\u00e3o Paulo, SP, Brasil"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"A. C. Camargo Cancer Center, S\u00e3o Paulo, SP, Brasil","institution_ids":["https://openalex.org/I3019035496"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006669933","display_name":"Jayr SCHMIDT-FILHO","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I3019035496","display_name":"AC Camargo Hospital","ror":"https://ror.org/03025ga79","country_code":"BR","type":"healthcare","lineage":["https://openalex.org/I3019035496"]}],"countries":["BR"],"is_corresponding":false,"raw_author_name":"Jayr SCHMIDT-FILHO","raw_affiliation_strings":["A. C. Camargo Cancer Center, S\u00e3o Paulo, SP, Brasil"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"A. C. Camargo Cancer Center, S\u00e3o Paulo, SP, Brasil","institution_ids":["https://openalex.org/I3019035496"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5120588063","display_name":"Bianca Batista CAL","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I3019035496","display_name":"AC Camargo Hospital","ror":"https://ror.org/03025ga79","country_code":"BR","type":"healthcare","lineage":["https://openalex.org/I3019035496"]}],"countries":["BR"],"is_corresponding":false,"raw_author_name":"Bianca Batista CAL","raw_affiliation_strings":["A. C. Camargo Cancer Center, S\u00e3o Paulo, SP, Brasil"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"A. C. Camargo Cancer Center, S\u00e3o Paulo, SP, Brasil","institution_ids":["https://openalex.org/I3019035496"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I3019035496"],"apc_list":{"value":0,"currency":"USD","value_usd":0},"apc_paid":null,"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.80366805,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"48","issue":null,"first_page":"107868","last_page":"107868"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/bispecific-antibodies","display_name":"bispecific antibodies","score":0.9990000128746033},{"id":"https://openalex.org/keywords/relapsed-refractory-multiple-myeloma","display_name":"relapsed/refractory multiple myeloma","score":0.9649999737739563},{"id":"https://openalex.org/keywords/treatment-efficacy","display_name":"treatment efficacy","score":0.7170000076293945},{"id":"https://openalex.org/keywords/treatment-safety","display_name":"treatment safety","score":0.7519999742507935},{"id":"https://openalex.org/keywords/real-world-evidence","display_name":"real-world evidence","score":0.7429999709129333},{"id":"https://openalex.org/keywords/brazil","display_name":"Brazil","score":0.36000001430511475}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9595000147819519},{"id":"https://openalex.org/C3020495827","wikidata":"https://www.wikidata.org/wiki/Q426141","display_name":"Bispecific antibody","level":4,"score":0.9229000210762024},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.460999995470047},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.39160001277923584},{"id":"https://openalex.org/C2908856526","wikidata":"https://www.wikidata.org/wiki/Q16252627","display_name":"Antibody therapy","level":4,"score":0.34310001134872437},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3100999891757965},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3052999973297119},{"id":"https://openalex.org/C2779473830","wikidata":"https://www.wikidata.org/wiki/Q1540899","display_name":"MEDLINE","level":2,"score":0.30230000615119934},{"id":"https://openalex.org/C3007834351","wikidata":"https://www.wikidata.org/wiki/Q82069695","display_name":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","level":5,"score":0.27790001034736633},{"id":"https://openalex.org/C3018913218","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody response","level":3,"score":0.27379998564720154},{"id":"https://openalex.org/C159047783","wikidata":"https://www.wikidata.org/wiki/Q7215","display_name":"Virology","level":1,"score":0.27079999446868896},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.26600000262260437},{"id":"https://openalex.org/C3008058167","wikidata":"https://www.wikidata.org/wiki/Q84263196","display_name":"Coronavirus disease 2019 (COVID-19)","level":4,"score":0.2628999948501587}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1016/j.htct.2026.107868","doi":"https://doi.org/10.1016/j.htct.2026.107868","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.htct.2026.107868","pdf_url":"https://www.sciencedirect.com/science/article/pii/S2531137926016159/pdf","source":{"id":"https://openalex.org/S2898598332","display_name":"Hematology Transfusion and Cell Therapy","issn_l":"2531-1379","issn":["2531-1379","2531-1387"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","ki-jl-1","poland-20","russia-white-list-3","scielo"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Hematology, Transfusion and Cell Therapy","raw_type":"journal-article"},{"id":"pmh:oai:doaj.org/article:1dc31f8a4a6c447ab85b9aeaf4b485fd","doi":null,"is_oa":false,"landing_page_url":"https://doaj.org/article/1dc31f8a4a6c447ab85b9aeaf4b485fd","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Hematology, Transfusion and Cell Therapy, Vol 48, Iss , Pp 107868- (2026)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.1016/j.htct.2026.107868","doi":"https://doi.org/10.1016/j.htct.2026.107868","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.htct.2026.107868","pdf_url":"https://www.sciencedirect.com/science/article/pii/S2531137926016159/pdf","source":{"id":"https://openalex.org/S2898598332","display_name":"Hematology Transfusion and Cell Therapy","issn_l":"2531-1379","issn":["2531-1379","2531-1387"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","ki-jl-1","poland-20","russia-white-list-3","scielo"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Hematology, Transfusion and Cell Therapy","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Observational Study","id":"https://openalex.org/study-designs/observational-study"}],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7223155019.pdf","grobid_xml":"https://content.openalex.org/works/W7223155019.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W7127360592","https://openalex.org/W7162648234","https://openalex.org/W4405041261","https://openalex.org/W4378716139","https://openalex.org/W7093123332","https://openalex.org/W4413421405","https://openalex.org/W4392236058","https://openalex.org/W4417013890","https://openalex.org/W4405050051","https://openalex.org/W4417006390"],"abstract_inverted_index":{"Background":[0],"Bispecific":[1],"antibodies":[2],"(BsAbs)":[3],"have":[4,435],"been":[5],"commercially":[6,56,379],"available":[7,57,380,465],"in":[8,28,45,59,194,210,283,305,320,331,352,382,401,408,458,476],"Brazil":[9,383],"since":[10],"2023":[11,92],"for":[12,223,270,274,278,432],"the":[13,51,109,177,389,394,438],"treatment":[14,38,142,197],"of":[15,32,35,55,180,196,212,238,288,325,369,393,426,461],"relapsed/refractory":[16],"multiple":[17],"myeloma":[18],"(R/R":[19],"MM).":[20],"Because":[21],"Brazilian":[22,67,477],"regulatory":[23],"approval":[24],"allows":[25],"their":[26],"use":[27,407],"triple-class\u2013exposed":[29],"patients":[30,60,76,138,155,172,354,409,427,478],"regardless":[31],"prior":[33,181,455],"lines":[34],"therapy,":[36],"real-world":[37,376],"patterns":[39],"may":[40,434,452],"differ":[41],"from":[42,108,133],"those":[43],"observed":[44],"pivotal":[46,402],"trials.":[47],"Aim":[48],"To":[49],"evaluate":[50],"efficacy":[52],"and":[53,71,93,99,104,176,188,220,226,233,241,251,276,286,291,308,323,334,344,363,384,413,451,471],"safety":[54,474],"BsAbs":[58,82,381,466],"with":[61,77,81,158,235,249,254,262,300,327,410,428,441,446,479],"R/R":[62,78,480],"MM":[63,79],"treated":[64,80,157,395],"at":[65,83,202],"a":[66,421,472],"cancer":[68],"center.":[69],"Materials":[70],"methods":[72],"We":[73],"retrospectively":[74],"reviewed":[75],"A.C.Camargo":[84],"Cancer":[85],"Center":[86],"(S\u00e3o":[87],"Paulo,":[88],"Brazil)":[89],"between":[90],"September":[91],"February":[94],"2026.":[95],"Baseline":[96],"characteristics,":[97],"efficacy,":[98],"toxicity":[100,346],"were":[101,106,131,169,173,191,201,208,348,448],"collected.":[102],"PFS":[103,245],"OS":[105,266],"calculated":[107],"first":[110],"BsAb":[111,141,439],"infusion.":[112],"ORR":[113,229],"was":[114,164,183,217,230,246,258,267],"defined":[115],"as":[116,126],"partial":[117],"response":[118],"(PR)":[119],"or":[120],"better.":[121],"Patients":[122],"receiving":[123],"talquetamab":[124,147,447],"(TAL)":[125],"bridging":[127],"therapy":[128,457],"to":[129],"CAR-T":[130,422,433],"excluded":[132],"survival":[134,398],"analyses.":[135],"Results":[136],"Twenty-five":[137],"contributed":[139],"30":[140],"episodes":[143],"(teclistamab":[144],"[TEC],":[145],"n=12;":[146],"[TAL],":[148],"n=14;":[149],"elranatamab":[150],"[ELRA],":[151],"n=4),":[152],"including":[153],"five":[154],"subsequently":[156],"TAL":[159,367],"after":[160],"TEC.":[161],"Median":[162,215,244,265],"age":[163],"66":[165],"years":[166],"(43\u201386),":[167],"60%":[168],"male,":[170],"all":[171],"triple-class":[174,204],"exposed,":[175],"median":[178],"number":[179],"LoTs":[182],"3":[184,314],"(2\u20136).":[185],"ISS":[186],"III":[187],"extramedullary":[189],"disease":[190,431],"each":[192],"present":[193],"36.7%":[195],"episodes,":[198],"while":[199],"56.7%":[200],"least":[203],"refractory.":[205],"High-risk":[206],"cytogenetics":[207],"identified":[209],"40%":[211],"evaluable":[213],"patients.":[214,462],"follow-up":[216],"22.2,":[218],"15.1,":[219],"9.3":[221],"months":[222,248,253,269,273],"TEC,":[224,271],"TAL,":[225,255,275],"ELRA,":[227],"respectively.":[228,243,336],"66.7%,":[231,332],"50.0%,":[232],"100%,":[234,242],"\u2265VGPR":[236],"rates":[237,445],"58.3%,":[239],"42.9%,":[240],"9.5":[247],"TEC":[250,301],"8.2":[252],"whereas":[256],"it":[257],"not":[259],"reached":[260],"(NR)":[261],"ELRA":[263,279],"(P=0.42).":[264],"24.3":[268],"15.3":[272],"NR":[277],"(P=0.68).":[280],"CRS":[281,297],"occurred":[282,298,304,316,319,351],"83.3%,":[284],"85.7%,":[285],"100%":[287],"TEC-,":[289],"TAL-,":[290],"ELRA-treated":[292],"patients,":[293,326,339],"respectively;":[294,310],"grade":[295,313,328,360],"\u22653":[296],"only":[299,311,356],"(16.7%).":[302],"ICANS":[303],"16.7%,":[306],"14.3%,":[307],"0%,":[309],"one":[312,357],"event":[315],"(TAL).":[317],"Infections":[318],"91.7%,":[321],"92.9%,":[322],"75.0%":[324],"3\u20134":[329],"infections":[330],"71.4%,":[333],"25.0%,":[335],"Among":[337],"TAL-treated":[338],"oral":[340],"(85.7%),":[341],"skin":[342],"(78.6%),":[343],"nail":[345],"(64.3%)":[347],"common.":[349],"Dizziness/ataxia":[350],"3/14":[353],"(21.4%);":[355],"patient":[358,365],"experienced":[359],"1":[361],"ataxia,":[362],"no":[364],"discontinued":[366],"because":[368],"neurologic":[370],"toxicity.":[371],"Discussion":[372],"This":[373],"study":[374],"provides":[375],"data":[377],"on":[378],"demonstrates":[385],"meaningful":[386,468],"responses":[387],"despite":[388],"high-risk":[390,415],"clinical":[391,469],"characteristics":[392],"population.":[396],"Shorter":[397],"than":[399],"reported":[400],"trials":[403],"likely":[404],"reflects":[405],"preferential":[406],"rapidly":[411],"progressive":[412],"clinically":[414],"disease.":[416,443],"As":[417],"our":[418],"institution":[419],"is":[420],"referral":[423],"center,":[424],"selection":[425],"more":[429],"favorable":[430],"further":[436],"enriched":[437],"cohort":[440],"aggressive":[442],"Infection":[444],"unexpectedly":[449],"high":[450],"partly":[453],"reflect":[454],"BCMA-targeted":[456],"nearly":[459],"one-third":[460],"Conclusion":[463],"Commercially":[464],"demonstrated":[467],"activity":[470],"manageable":[473],"profile":[475],"MM.":[481]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2026-10-22T00:00:00"}